Sangram Raut,
University of North Texas Health Science Center, USA
Title: rHDL: A versatile drug/biologic delivery platform
Biography
Biography: Sangram Raut,
Abstract
Lipoprotein-based technologies could address many of the concerns of traditional chemotherapy via their ability to selectively deliver their payload to cancer cells and tumors via a receptor-mediated mechanism. Moreover, they have been shown to be equally effective for targeted diagnostic imaging. Specifically, it has been shown that malignant cells consistently overexpress Scavenger receptor class B type 1 (SR-B1) receptors compared to normal cells which are the receptor for lipoprotein based nanoparticles. The therapeutic index of many cytotoxic drugs can thus be significantly improved by enhancing the selective delivery and accumulation of the therapeutic agent in malignant cells and tumors vs. healthy cells and tissue, thus avoiding toxic side effects. Lipoprotein-based nanoparticles have the potential to perform tumor selective delivery and thus overcome these limitations. We will present some of our recent findings and progress in the area of lipoprotein drug delivery. Consequently, reconstituted (synthetic) lipoproteins have proven to be a superior biocompatible drug-delivery platform and thus have great potential for cancer theranostics.